Pharmacokinetic Modeling of Hydrocortisone by Including Protein Binding to Corticosteroid-Binding Globulin

Eric Rozenveld 1, Nieko Punt 1,2, Martijn van Faassen 3, André P. van Beek 4 and Daan J. Touw 1,5,*

1 Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; e.r.rozenveld@student.rug.nl (E.R.); punt@medimatics.nl (N.P.)
2 Medimatics, 6229 HR Maastricht, The Netherlands
3 Department of Laboratory Medicine, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; h.j.r.van.faassen@umcg.nl
4 Department of Endocrinology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; a.p.van.beek@umcg.nl
5 Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, 9713 GZ Groningen, The Netherlands

* Correspondence: d.j.touw@umcg.nl

Abstract: Background: Patients with adrenal insufficiency are treated with oral hydrocortisone (HC) to compensate for the loss of endogenous cortisol production. Intrinsic imperfections of cortisol replacement strategies in mimicking normal cortisol secretion are the underlying cause of the increased morbidity and mortality of patients suffering from secondary adrenal insufficiency (SAI). To improve oral hydrocortisone substitution therapy, a better understanding of its pharmacokinetics (PK) is necessary. The previous PK model did not include protein binding. It is known that protein binding can impact hydrocortisone pharmacokinetics. The aim of this study is to describe HC pharmacokinetics including the protein-binding state using Edsim++ (Mediware, Prague) pharmacokinetic modeling software, paving the way for an in-silico tool suitable for drug delivery design. Methods: A total of 46 patients with SAI participated in a randomized double-blind crossover study. Patients randomly received a low dose of HC (0.2–0.3 mg/kg body weight/day) for 10 weeks, followed by a high dose (0.4–0.6 mg/kg body weight/day) for another 10 weeks, or vice versa. Plasma samples were obtained and analyzed for free and total hydrocortisone. Single compartment population pharmacokinetic analysis was performed using an extended Werumeus-Buning model built in Edsim++. This model includes a mathematical approach for estimating free cortisol by Nguyen et al., taking the protein binding of HC to albumin and hydrocortisone-binding globulin (CBG, transcortin) into consideration, as well as different states of CBG which affect binding kinetics to HC. The goodness of fit for observed versus predicted values was calculated. Results and conclusions: Nguyen’s formula for free cortisol estimation was successfully implemented in a pharmacokinetic model. The model shows high Spearman’s correlation for observed versus predicted hydrocortisone concentrations. Significantly higher correlations (Spearman’s r, 0.901 vs. 0.836) between total and free hydrocortisone AUC24 (area-under the curve over 24 h) are found when comparing new and old models. This new model was used to simulate the plasma concentration–time behavior of a more suitable hydrocortisone formulation.

Keywords: hydrocortisone; secondary adrenal insufficiency; pharmacokinetic modeling; hydrocortisone-protein binding; CBG; transcortin; Edsim++

1. Introduction

Cortisol is an essential hormone that affects almost every organ in the body. It plays many important roles, such as regulating the body’s stress response and metabolism. In patients suffering from secondary adrenal insufficiency (SAI), the insufficient secretion of ACTH due to (treatment of) pituitary disease is the cause of insufficient adrenal cortisol production [1,2]. A deficiency in cortisol levels leads to significant health risks, including
the life-threatening risk of an Addison crisis [3]. Therapy for SAI is based on substituting cortisol by administering immediate-release hydrocortisone tablets. This substitution has proved to be successful when treating SAI, improving both morbidity and mortality. Nevertheless, patients suffering from SAI are subjected to a decreased quality of life and reduced life span when compared with healthy subjects [4]. It is likely that part of this is caused by the intrinsic imperfections of hydrocortisone replacement strategies in mimicking normal cortisol secretion [5].

Recent studies suggest that the plasma concentration of hydrocortisone replacement therapy is heavily subjected to inter-individual variability, giving rise to side effects such as daily fatigue and an increased risk of cardiovascular disease [5]. In addition, studies have shown that the protein binding of hydrocortisone to transcortin (cortisol-binding globulin—CBG) and albumin can affect the pharmacokinetic parameters of hydrocortisone [6]. In order to develop and evaluate more appropriate substitution therapies, a better understanding of the pharmacokinetic properties of HC with protein binding is needed.

Approximately 80–90% of hydrocortisone binds to CBG, which can be found within the circulation [7]. Only the free fraction of hydrocortisone is responsible for its physiological function. Changes in the binding kinetics of hydrocortisone to CBG can potentially impact free hydrocortisone concentration, which is known to show inter-individual variability [8]. Calculating this could therefore be beneficial for treatment [9–11]. CBG can exist in an intact state (CBGi) or cleaved state (CBGe) [12]. CBGe has a 10-fold lower affinity to hydrocortisone than CBGi [13]. This state can be influenced by neutrophil elastase and chronic inflammation [14]. To understand and describe the pharmacokinetics of hydrocortisone, pharmacokinetic models can be used. An example of such a model is the model made by Werumeus-Buning et al. [5]. A drawback of the Werumeus-Buning model is that for total and for free hydrocortisone, separate models are developed. Combining both models could potentially increase their predictive power. This study focused on improving the pharmacokinetic model made by Werumeus-Buning et al. by including protein binding (albumin and CBGe-CBGi) [6] in order to optimize substitution strategies with hydrocortisone. This model was used to simulate a dosing strategy for patients suffering from SAI. This new dosing strategy is currently under development.

2. Materials and Methods

2.1. Subjects and Measurements

This study is a post hoc analysis of the data generated by Werumeus-Bunning et al. [5] by adding albumin and CBG binding to the model. The details of this study design have been published in detail previously; the patients and intervention are the same as described in the study by Werumeus-Buning et al. [5] and are summarized in brief here. The study was approved by the ethical committee of the University Medical Center Groningen, The Netherlands. All patients gave written informed consent before entering the study. The study was registered with ClinicalTrial.gov, NCT01546922.5.

Sixty-three patients with SAI were recruited for a randomized double-blind trial between May 2012 and June 2013 from the outpatient clinic at the University Medical Center Groningen. A total of 47 patients completed all study procedures. Due to a violation of the study protocol, one patient was excluded. All patients were on a stable glucocorticosteroid replacement therapy for at least six months prior to the study. Renal and liver parameters were tested and perceived to be normal in each subject. Patients that were known to use active CYP3A4 inhibitors or inducers were excluded. Further inclusion and exclusion criteria are published in detail elsewhere [5].

Patients were randomly allocated to receive a low dose of HC (0.2–0.3 mg HC/kg body weight/day) for ten weeks followed by a higher dose (0.4–0.6 HC/kg body weight/day) for ten weeks or in reverse order. HC (immediate release tablets) were given in three divided doses (before breakfast, before lunch, and before dinner). The exact dosing scheme has been previously described in detail [5]. Patients were allowed to double or triple their dose in case of illness. Patients were strictly instructed not to take a double or triple dose in the
week preceding the visiting day. On visit days, patients were instructed to take their HC dose at 7:00 h and 8:00 h blood samples were drawn following a normal protocol (upright sitting, after a short period of rest). This procedure was repeated after approximately 5 h.

Plasma free hydrocortisone, total hydrocortisone and cortisone levels were measured using isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) at the laboratory of the UMCG. An internal standard of hydrocortisone 13C3 was used. The method that was used was described by Hawley et al. [15]. Plasma equilibrium dialysis for free cortisol and cortisone was performed as described by Fiers et al. [12], the only difference being that we used 10 kD cellulose membranes (Harvard Apparatus). Total serum CBG concentrations were measured in duplicate using a radioimmunoassay (IBL International GmbH, Hamburg, Germany) [16]. Albumin was determined with the bromocresol green method on a Roche Modular ISE/P (Roche Diagnostics, Mannheim, Germany).

2.2. Model Development

A 1-compartment pharmacokinetic (PK) model was developed using the object-oriented visual PK/PD modeling tool Edsim++ (version 1.88, Mediware, Prague, based on MwPharm++) [17–19] as is shown in Supplementary S4 Figure S1. With Edsim++ it was possible to develop a visual object-oriented model with an integrated Nguyen formula [20]. Previous analysis was also conducted using an earlier version of KinPop++ (Werumeus-Buning et al.), which is part of the Edsim++ PKPD modeling platform. Using KinPop++ would allow us to easily compare both models. A special compartment class (XCortisol) was developed for modeling the protein (albumin, CBGe-CBGi) binding of hydrocortisone. The visual Edsim++ representation of the model was exported to Berkely Madonna (Supplementary S1) and RxODE (Supplementary S2) for internal model validation purposes. This compartment model employs Equation 1 derived from Nguyen et al. [20], which is based on earlier work from Dorin et al. [21] for the estimation of bound (‘total’) and unbound (‘free’) hydrocortisone. Edsim++ was used for the population analysis of the free and total hydrocortisone plasma levels using an iterative two-stage Bayesian (ITSB) technique [22]. In Equation (1) $K_A$ represents the affinity of albumin for hydrocortisone, $K_C$ represents the affinity for intact CBG (CBGi) for hydrocortisone and $K_{C*}$ represents the affinity of cleaved CBG (CBGe) for hydrocortisone. $\text{Tot} F = \text{total concentration hydrocortisone.}$

$$\text{Tot} F = [F] \times 1 + \frac{\text{Tot} A}{K_A \times [F]} + \frac{\text{Tot} C}{K_C \times [F]} + \frac{\text{Tot} C^*}{K_{C^*} \times [F]}$$  \hspace{1cm} (1)

The model can operate in two modes (free or total hydrocortisone concentration). In this study, we used the free hydrocortisone mode, in which hydrocortisone elimination is driven by the free concentration. The total concentration is then calculated from the free concentration.

The population values for the clearance (236 L/h) and volume of distribution (474 L) as found by Werumeus-Buning et al. [5] (Table 1) were used as first estimates in the new model. Bioavailability was set to a literature value of 0.96 [9,14]. Dissociation constants were derived from Nguyen et al. [20] and set as follows: $K_A$, $K_C$ and $K_{C^*}$ were set to 330,000 nM, 330 nM and 33 nM, respectively. The ratio between CBGe-CBG was individually predicted for every patient and is shown as an RC value, calculated as either $\text{CBGe} = \text{RC} \times \text{CBG}$ or $\text{CBGi} = (1 - \text{RC}) \times \text{CBG}$.
Table 1. Parameters of the population model developed from our patient data (high dose and low dose), and the free fraction of hydrocortisone. Residual variability is 1.1 mg/mL (additive) and 9.5% (proportional). Shrinkage is shown in %.

| Parameter | New Model | CV (%) | Shrinkage (%) | Old Model [5,6] | CV (%) | p-Value (Old vs. New) |
|-----------|-----------|--------|---------------|-----------------|--------|----------------------|
| V (L)     | 405       | 55%    | 1.9           | 474             | 54%    | 0.11                 |
| CL (L/h)  | 226       | 51%    | 1.1           | 236             | 46%    | 0.67                 |
| RC ^1     | 0.13      | 85%    | 19.8          | -               | -      | -                    |
| Spearman’s r (AUC24 for free versus total hydrocortisone) | 0.901 | - | 0.836 | - | <0.000001 |
| Confidence interval | 0.852 to 0.935 | - | 0.757 to 0.891 | - | - |
| p value (two-tailed) | <0.0001 | - | <0.0001 | - | - |
| N         | 88        | -      | 88            | -               | -      | -                    |

^1 RC = ratio between CBGe (corticosteroid-binding globulin cleaved) and CBG. ^2 CV (%) is the interindividual variation present in both our model and that of Werumeus-Buning.

By using Equation (1) and data from Werumeus-Buning et al. [5,6] it was possible to calculate new values for the clearance and volume of distribution that takes protein binding into account (Table 1). This model can therefore use both free and total hydrocortisone values in one model.

2.3. Iterative Two-Stage Bayesian

The ITSB method is currently the only method supported by KinPop and has been proven to perform well in both rich data sets [22] and in sparse data sets [23]. Moreover, an ITSB analysis and its individual estimates are hardly affected by most data registration errors [24].

2.4. Statistics and Evaluation

Statistics were carried out using GraphPad Prism v 8.0. Spearman’s r correlation was calculated to compare the observed versus predicted values. Significance was calculated with an unpaired t-test. To assess the validation of the obtained results, a goodness-of-fit plot and an accessory weighted residual graph were plotted.

2.5. Simulated Plasma Curves with a New Dosing Strategy

For the development of a new dosing strategy for SAI therapy with hydrocortisone, it was deemed most beneficial for patients that the hydrocortisone plasma concentration–time behavior be as similar as possible to the endogenous cortisol plasma values. To achieve a simulation of close-to-endogenous cortisol values, it was concluded that hydrocortisone should be dosed twice daily. One dose in the evening has a sufficient dissolution lag time to give a peak plasma concentration in the morning. The second dose is administered in the morning with sufficient slow absorption to sustain the hydrocortisone release during the day. From the pharmacokinetics, an evening dose of 9 mg was taken and a morning dose of 5 mg. For the evening dose, a dissolution lag time of 4 h was used and a fractional absorption rate of 0.7 h⁻¹. For the slow absorption of the morning dose, a zero-order dissolution rate of 0.8 mg/h was chosen.

3. Results

3.1. Concentration of Hydrocortisone Bound to Protein

Figure 1 shows the binding state of hydrocortisone with CBG for a typical patient (weight; 70 kg, height; 1.75 m) receiving a dose of 10-5-2.5 mg at t = 7:00, 13:00 and 19:00 h (morning, midday, and evening) of immediate-release HC. Binding to CBG, expressed as the fraction unbound (fu), showed variation over time (dotted line). The concentration of hydrocortisone bound to protein (CBG and albumin) was simulated, as well as the free unbound form of hydrocortisone.
of hydrocortisone bound to protein (CBG and albumin) was simulated, as well as the free unbound form of hydrocortisone.

Figure 1. Simulation of free and total hydrocortisone plasma levels in a typical patient (weight; 70 kg, height; 1.75 m) receiving a dose of 10-5-2.5 mg of immediate-release HC at 7, 13 and 19 h. This figure shows the concentration of hydrocortisone that is bound to CBG and albumin (solid line, conc. bound—nM) and the concentration of hydrocortisone unbound (gray line) (conc. unbound—nM). Variable protein binding to CBG is also shown as a fraction (fraction unbound—dashed line, right axis).

3.2. Comparing New Model to Older Model

The results in Table 1 show the estimated population pharmacokinetic parameters for total hydrocortisone in the new model. Our model included the estimated ratio of CBGe-CBG. Both the clearance and the volume of distribution were found to be slightly lower, although this result was not significant ($p = 0.11$). The difference in CL between both models was also not significant ($p = 0.67$). Interindividual variance was 55% for V, 51% for Cl and 85% for RC value. Additionally, the AUC$_{24}$ values for total versus free cortisol were calculated and compared between the new model and the values of the older model.

3.3. Goodness-of-Fit Plots

In order to assess the performance of the model, goodness-of-fit plots and residual plots were generated for population and individual predicted values (Figures 2 and 3). An overall correlation of $r = 0.9985$ could be found for the individual prediction with measured data, with a 95% confidence interval of 0.9981 to 0.9988. For population values, $r = 0.9542$ with a 95% confidence interval of 0.9430 to 0.9632. Residual plots are shown in Supplementary S4 Figure S2.
Figure 2. Goodness-of-fit plots of both population and individual parameters. This plot shows the agreement between observed and predicted concentration by model. Agreement is both visualized in the plots (red line as unity), as well as calculated using Spearman’s $r$ correlation coefficient. Black color shows the total hydrocortisone concentration (bound to CBG and free). Grey shows the free hydrocortisone concentration. Spearman’s $r$ for individual prediction is 0.999. Spearman’s $r$ for population prediction is 0.954. (a) shows population prediction. (b) shows individual predictions.

Figure 3. Weighted residual plots of both population (upper) and individual predictions (lower).
4. Discussion

4.1. Key Findings

A new population pharmacokinetic model of hydrocortisone was developed as an improvement upon previously developed models by considering the different affinities for hydrocortisone for the two forms of CBG: iCBG and eCBG. Because the protein binding of hydrocortisone plays a role in hydrocortisone kinetics, it is argued that this model gives a better prediction of free or total hydrocortisone in the human body.

4.2. Interpretation and Implications

Table 1 shows the model parameters for V and CL, including a mean RC value of 0.13, using the population model. This is in concordance with the literature [9] and is therefore a plausible outcome of the model. A lower volume of distribution was found for free hydrocortisone when comparing the new population calculations with the Werumeus-Buning [5,6] calculations. Because the free fraction is dependent on CBG binding, and CBG is mainly found in the bloodstream, a lower V is observed and expected in this new calculation. The new model has both free and total hydrocortisone in one model, whereas the old model had one model for free and one model for total hydrocortisone. With the new model, it is therefore possible to easily calculate unbound hydrocortisone values from total hydrocortisone values. When comparing AUC$_{24}$ values, a higher correlation can be observed between free hydrocortisone AUC$_{24}$ values versus total hydrocortisone AUC$_{24}$ values. This implies that the model is in fact working as intended, as a higher correlation between the two values would be expected when protein binding is factored.

Figure 1 shows that the plasma values of hydrocortisone bound to CBG are higher than the unbound values, as is in concordance with literature [8–10,20]. The plot also shows changes in the unbound-bound fraction over time, and that this is not one static value.

Figure 2 shows the predicted values based on the population parameter values. A good model can predict individual values with high accuracy. For the population prediction the model has an r value of 0.9452. High overall correlation can be found (r = 0.9985) when comparing the observed values with the predicted values for the individual fit. Thus, the model is able to predict hydrocortisone plasma concentrations with high accuracy. This also gives credibility to the curve as is seen in Figure 1 for a typical patient, but also for every individually fitted patient. It is also possible to gain new information and calculate important parameters such as the area under the curve (AUC) with this model.

By including protein binding in our model, it permits a better evaluation of adrenal function (when measuring total cortisol and CBG), which is particularly useful in patients with altered CBG concentrations. Altered CBG concentrations can occur in patients who have high neutrophil elastase activity [10,12,19].

The simulated curve and conventional therapy curve in Figure 4 show that the conventional therapy lacks the early rise in cortisol between 3 and 6 h in the morning for this patient. It is therefore argued that an evening dose should have a sufficient lag time to mimic as closely as possible the endogenous cortisol plasma concentration.
with oral contraceptives [30].

was measured, instead of CBGi alone. Therefore, the RC ratio needed to be estimated

patients with both primary and secondary adrenal insufficiency. However, these residual

values of the RC ratio (as is addressed by Nguyen et al. [20]).

studies found that CBG concentrations increased rapidly during the first cycle of treatment

corticosteroid concentrations were quantitatively low and might not be of relevance.

steroid production is likely to continue during treatment in a considerable percentage of

significance. The study conducted by Vulto et al. [29] described that adrenal corticos-

also affect the outcome of the model [28]. It is, however, still unclear if this is of clinical

difference in hydrocortisone exposure is \( \leq \) in influence the hydrocortisone dosing strategy. However, Melin et al. [27] found that the

morning that has an extended-release profile (at 7:00 h). Evening dose is 9 mg and morning dose is

5 mg. Details on the characteristics of both doses can be found in the text.

4.3. Limitations

Some limitations of this study need to be addressed. First, total CBG (CBGi + CBGe) was measured, instead of CBGi alone. Therefore, the RC ratio needed to be estimated by the model rather than measured. Measuring CBG directly could lead to better results. However, as Table 1 shows, an estimated RC of 0.13 is plausible compared to the literature values of the RC ratio (as is addressed by Nguyen et al. [20]).

Furthermore, our model does not include factors such as steroid competition (as hydrocortisone is not the only steroid that can bind to CBG). Concentrations of steroids such as testosterone and progesterone may vary between individuals (as is described in Gudmand-Hoeyer et al. [25]), and in turn influence binding to CBG [14]. CBG also actively regulates hydrocortisone release [26]. Currently, this is not quantitatively described in the literature. Some study subjects also took steroid supplements, which could have influenced the result in this study.

CBG has a circadian rhythm. One could argue that the circadian rhythm of CBG can influence the hydrocortisone dosing strategy. However, Melin et al. [27] found that the difference in hydrocortisone exposure is \( \leq 12.2\% \) between the times of highest and lowest CBG concentrations; therefore, hydrocortisone dose adjustment based on the time of dosing to adjust for the CBG concentrations is unlikely to be of clinical benefit.

Inter-individual variability in the production of endogenous hydrocortisone could also affect the outcome of the model [28]. It is, however, still unclear if this is of clinical significance. The study conducted by Vulto et al. [29] described that adrenal corticosteroid production is likely to continue during treatment in a considerable percentage of patients with both primary and secondary adrenal insufficiency. However, these residual corticosteroid concentrations were quantitatively low and might not be of relevance.

CBG concentration can also be different when using oral contraceptives, as some studies found that CBG concentrations increased rapidly during the first cycle of treatment with oral contraceptives [30].

Figure 4. Simulated example of desired therapy (thick black line) with endogenous cortisol (dashed line) and conventional therapy (black line). Typical patient (weight; 70 kg, height; 1.75 m) receiving a dose of 10-5-2.5 mg of immediate-release HC at 7, 13 and 19 h. The simulated curve has two hydrocortisone doses, one in the evening with a lag time of approx. 4 h (23:00 h), and one in the morning that has an extended-release profile (at 7:00 h). Evening dose is 9 mg and morning dose is 5 mg. Details on the characteristics of both doses can be found in the text.
4.4. Recommendations

It is interesting to use this model to further investigate optimal hydrocortisone therapy in patients suffering from adrenal insufficiency. In normal subjects, endogenous hydrocortisone levels steadily rise from around 3:00–5:00 h and peak at around 7:00 [31]. With conventional hydrocortisone therapy, patients administer their daily dose early in the morning, usually at breakfast. As a result, patients administer their HC dose at an inappropriate time, which in turn decreases overall well-being, as was investigated by both Werumeus-Buning et al. [5] and Simon et al. [11].

Our new model can easily be used to simulate hydrocortisone serum concentrations based on drug formulations with different types of release profiles, e.g., for coated HC tablets with a dissolution lag time (modified release) as a substitution for conventional immediate-release HC therapy to further improve therapy in SAI patients. These data can then be used for in vitro studies to further optimize hydrocortisone formulations.

Using this model to investigate in vivo release characteristics can aid drug development. This development is currently in progress, as new therapeutic interventions are simulated with the help of this model.

5. Conclusions

A model is developed describing total hydrocortisone and free hydrocortisone by accounting for the protein binding of hydrocortisone to albumin, iCBG and eCBG. This model provides a more accurate fit than the previously used models for calculating the concentration of free or total hydrocortisone in the circulation.

This model can be used in future studies towards drug development, hydrocortisone pharmacokinetics and dosing simulations. Unbound cortisol can be calculated in a simple and reliable way by measuring total cortisol and CBG and permits a better evaluation of adrenal function, which is particularly useful in patients with altered CBG concentrations.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics14061161/s1, Supplementary S1: Berkeley Madonna script used in Edsim++; Supplementary S2: RxODE Script; Supplementary S3: Script Symbols; Supplementary S4 Figure S1: Model build in Edsim++; Figure S2: Simulated curves for an improved therapy design.

Author Contributions: Conceptualization, E.R., D.J.T. and A.P.v.B.; methodology, N.P.; software, N.P.; validation, E.R. and N.P.; formal analysis, N.P.; investigation, E.R.; resources, M.v.F.; data curation, N.P.; writing—original draft preparation, E.R.; writing—review and editing, D.J.T.; visualization, E.R.; supervision, A.P.v.B. and D.J.T.; project administration, D.J.T.; funding acquisition, D.J.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was registered with ClinicalTrial.gov, NCT01546922.5.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest, with the exception of N.P., who is president of Medimatics, a company that provides consulting services on medical information systems located in Maastricht, The Netherlands.

References

1. Zelissen, P.M. Bijnierschorsinsufficiëntie. Bijblijven 2015, 31, 278–289. [CrossRef]
2. Arlt, W.; Allolio, B. Adrenal Insufficiency. Lancet 2003, 361, 1881–1893. Available online: http://www.sciencedirect.com/science/article/pii/S0140673603134927 (accessed on 23 April 2021). [CrossRef]
3. Sapolsky, R.M.; Romero, L.M.; Munck, A.U. How Do Glucocorticoids Influence Stress Responses? Prep. Actions Endocr. Rev. 2000, 21, 55–89.
4. Hahner, S.; Loeffler, M.; Fassnacht, M.; Weismann, D.; Koscher, A.-C.; Quinkler, M.; Decker, O.; Arlt, W.; Allolio, B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. *J. Clin. Endocrinol. Metab.* 2007, 92, 3912–3922. [CrossRef]

5. Buning, J.W.; Brummelman, P.; Koerts, J.; Dullaart, R.P.; Berg, G.V.D.; van der Klauw, M.M.; Tucha, O.; Wolffenbuttel, B.H.; van Beek, A.P. The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency—Results from a randomized controlled trial. *Psychoneuroendocrinology* 2015, 55, 36–47. [CrossRef]

6. Werumeus Buning, J.; Touw, D.J.; Brummelman, P.; Dullaart, R.P.E.; van den Berg, G.; van der Klauw, M.M.; van Beek, A.P. Pharmacokinetics of oral hydrocortisone—Results and implications from a randomized controlled trial. *Metab. Clin. Exp.* 2017, 71, 7–16. [CrossRef]

7. Louisa, L.B. Cutler The adrenal cortex. *Williams Textb. Endocrinol.* 2011, 10, 227–254.

8. Perogamvros, I.; Aarons, L.; Miller, A.G.; Trainer, P.J.; Ray, D.W. Corticosteroid-binding globulin regulates cortisol pharmacokinetics. *Clin. Endocrinol.* 2011, 74, 30–36. [CrossRef]

9. Coolens, J.-L.; Van Baelen, H.; Heyns, W. Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. *J. Steroid Biochem.* 1987, 26, 197–202. [CrossRef]

10. Lewis, J.G.; Elder, P.A. The reactive centre loop of corticosteroid-binding globulin (CBG) is a protease target for cortisol release. *Mol. Cell. Endocrinol.* 2014, 384, 96–101. [CrossRef]

11. Simon, N.; Castinetti, F.; Ouliac, F.; Lesavre, N.; Brue, T.; Oliver, C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. *Clin. Pharmacokinet.* 2010, 49, 455–463. [CrossRef] [PubMed]

12. Fiers, T.; Wu, F.; Mogi, F.; Vanderschueren, D.; Lapauw, B.; Kaufman, J.M. Reassessing Free-Testosterone Calculation by Liquid Chromatography-Tandem Mass Spectrometry Direct Equilibrium Dialysis. *J. Clin. Endocrinol. Metab.* 2018, 103, 2167–2174. [CrossRef] [PubMed]

13. Henley, D.; Lightman, S.; Carrell, R. Cortisol and CBG—Getting cortisol to the right place at the right time. *Pharmacol. Ther.* 2016, 166, 128–135. [CrossRef] [PubMed]

14. Lin, H.Y.; Underhill, C.; Gardill, B.R.; Muller, Y.A.; Hammond, G.L. Residues in the human corticosteroid-binding globulin reactive center loop that influence steroid binding before and after elastase cleavage. *J. Biol. Chem.* 2009, 284, 884–896. [CrossRef]

15. Hawley, J.M.; Owen, L.J.; MacKenzie, F.; Mussel, C.; Cowen, S.; Keevil, B.G. Candidate reference measurement procedure for the quantitative Total serum cortisol with LC–MS/MS. *Clin. Chem.* 2016, 62, 262–269. [CrossRef] [PubMed]

16. Robinson, P.A.; Langley, M.S.; Hammond, G.L. A solid-phase radioimmunoassay for human corticosteroid binding globulin. *J. Endocrinol.* 1985, 104, 259–267. [CrossRef] [PubMed]

17. Vinks, A.A.; Punt, N.; Menke, F.; Kirkendall, E.; Butler, D.; Duggan, T.J.; Cortezzo, D.E.; Kiger, S.; Dietrich, T.; Spencer, P.; et al. Electronic Health Record—Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. *Clin. Pharmacol. Ther.* 2020, 107, 186–194. [CrossRef] [PubMed]

18. Taylor, Z.L.; Mizuno, T.; Punt, N.C.; Baskaran, B.; Sainz, A.N.; Shuman, W.; Felicelli, N.; Vinks, A.A.; Heldrup, J.; Ramsey, L.B. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. *Clin. Pharmacol. Ther.* 2020, 108, 635–643. [CrossRef] [PubMed]

19. Mouton, J.W.; A Vinks, A.; Punt, N.C. Pharmacokinetic-Pharmacodynamic Modeling of Activity of Ceftazidime during Continuous and Intermittent Infusion. *Antimicrob. Agents Chemother* 1997, 41, 733–738. [CrossRef]

20. Nguyen, P.T.T.; Lewis, J.G.; Sneyd, J.; Lee, R.S.F.; Torpy, D.J.; Shorten, P.R. Development of a formula for estimating plasma free cortisol concentration from a measured total cortisol concentration when elastase-cleaved and intact corticosteroid binding globulin coexist. *J. Steroid Biochem.* 2014, 141, 146–25. [CrossRef] [PubMed]

21. Dorin, R.I.; Pai, H.K.; Ho, J.T.; Lewis, J.G.; Torpy, D.J.; Urban, F.K.; Qualls, C.R. Validation of a simple method of estimating plasma free cortisol: Role of cortisol binding to albumin. *Clin. Biochem.* 2009, 42, 64–71. [CrossRef] [PubMed]

22. Proost, J.H.; Evelend, D.J. Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. *Pharm. Res.* 2006, 23, 2748–2759, Erratum in *Pharm. Res.* 2007, 24, 1599. [CrossRef] [PubMed]

23. van der Meer, A.F.; Touw, D.J.; Marcus, M.A.; Neef, C.; Proost, J.H. Influence of erroneous patient records on population pharmacokinetic modeling and individual Bayesian estimation. *Drug Monit.* 2012, 34, 526–534. [CrossRef] [PubMed]

24. Girard, P.; Mentre, F. A Comparison of Estimation Methods in Nonlinear Mixed Effects Models Using a Blind Analysis. In *Proceedings of the Annual Meeting of the Population Approach Group in Europe, Pamplona, Spain, 5 January 2016*.

25. Gudmand-Høyer, J.; Ottesen, J.T. Analysis and validation of a new extended method for estimating plasma free cortisol including neutrophil elastase and competition from other steroids. *J. Steroid Biochem. Mol. Biol.* 2018, 181, 109–124. [CrossRef]

26. Murphy, B. Corticosteroid-binding globulin. In *Stress Science: Neuroendocrinology; Fink, G., Ed.; Academic Press: San Diego, CA, USA*, 2009; pp. 245–252.

27. Melin, J.; Hartung, N.; Parra-Guillen, Z.P.; Whitaker, M.J.; Ross, R.J.; Kloft, C. The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing. *Clin. Endocrinol.* 2019, 91, 33–40. [CrossRef]

28. Zhang, Q.; Chen, Z.; Chen, S.; Xu, Y.; Deng, H. Intraindividual stability of cortisol and cortisone and the ratio of cortisol to cortisone in saliva, urine and hair. *Stereoids* 2017, 118, 61–67. [CrossRef]

29. Vulto, A.; Berghoorsdottir, R.; Van Faassen, M.; Kema, I.P.; Johannsson, G.; Van Beek, A.P. Residual endogenous corticosteroid production in patients with adrenal insufficiency. *Clin. Endocrinol.* 2019, 91, 383–390. [CrossRef]
30. Wiegratz, I.; Kutschera, E.; Lee, J.H.; Moore, C.; Mellinger, U.; Winkler, U.H.; Kuhl, H. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. *Contraception* 2003, 67, 25–32. [CrossRef]

31. Mah, P.M.; Jenkins, R.C.; Rostami-Hodjegan, A.; Newell-Price, J.; Doane, A.; Ibbotson, V.; Tucker, G.T.; Ross, R.J. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. *Clin. Endocrinol.* 2004, 61, 367–375. [CrossRef]